Phase II pilot study of nab-paclitaxel in patients with metastatic or unresectable urothelial cancer previously treated with cisplatin-based chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2019
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 31 Mar 2019 Status changed from active, no longer recruiting to completed.
- 26 Mar 2016 Status changed from recruiting to active, no longer recruiting.
- 08 Oct 2014 New trial record